Advanced Renal Cell Carcinoma Pipeline 2024 | Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune

DelveInsight’s, “Advanced Renal Cell Carcinoma Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in Advanced Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Advanced Renal Cell Carcinoma Research. Learn more about our innovative pipeline today! @ Advanced Renal Cell Carcinoma Pipeline Outlook

Key Takeaways from the Advanced Renal Cell Carcinoma Pipeline Report

July 2024:- Ipsen- A Phase II, Multicentre, Open-label Study of Cabozantinib as 2nd Line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors. The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.
June 2024:- Bristol-Myers Squibb-  A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors. The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.
DelveInsight’s Advanced Renal Cell Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 60+ pipeline therapies for Advanced Renal Cell Carcinoma treatment.
The leading Advanced Renal Cell Carcinoma Companies such as Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, Molecure S.A., Daiichi Sankyo, Janux Therapeutics, MedImmune, Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Chongqing Precision Biotech Co., Ltd, Pfizer, Exelixis, BeiGene, Xencor, and others.
Promising Advanced Renal Cell Carcinoma Therapies such as KY1044, JK08, Pembrolizumab, Savolitinib, Sunitinib, TT-10, and others.

Stay informed about the cutting-edge advancements in Advanced Renal Cell Carcinoma treatments. Download for updates and be a part of the revolution in oncology care @ Advanced Renal Cell Carcinoma Clinical Trials Assessment

Advanced Renal Cell Carcinoma Emerging Drugs Profile

Belzutifan: Merck Sharp & Dohme

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2a). Belzutifan binds to HIF-2a, and in conditions of hypoxia or impairment of VHL protein function, belzutifan inhibits the HIF-2a-HIF-1ß interaction, leading to reduced transcription and expression of HIF-2a target genes. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of advanced renal cell carcinoma.

IPI-549: Infinity Pharmaceuticals

Eganelisib is a first-in-class, oral, once-daily, immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma). Selective PI3K-gamma inhibition represents a unique and potentially transformative approach within immuno-oncology (I/O), and IPI-549 has the potential to be a first-in-class therapy. Preclinical research conducted by Infinity and academic collaborators demonstrates that IPI-549 works by reprogramming key immune suppressive cells (called M2 macrophages or myeloid derived suppressor cells (MDSCs)) within the tumor microenvironment from a pro-tumor function to an anti-tumor function, decreasing immune suppression and increasing immune activation, ultimately leading to the activation and proliferation of T cells that can attack cancer cells. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of advanced renal cell carcinoma.

JANX008: Janux Therapeutics

JANX008 is an EGFR-TRACTr that is designed to overcome CRS and known on-target EGFR healthy tissue toxicities. Epidermal growth factor receptor (EGFR) is a clinically validated target highly expressed on many solid tumors that are being underserved by current therapies. JANX008 targets EGFR for the treatment of multiple solid cancers including, but not limited to, colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of advanced renal cell carcinoma.

Learn more about Advanced Renal Cell Carcinoma Drugs Opportunities in our groundbreaking Advanced Renal Cell Carcinoma research and development projects @ Advanced Renal Cell Carcinoma Unmet Needs

Advanced Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Advanced Renal Cell Carcinoma Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Discover the latest advancements in Advanced Renal Cell Carcinoma treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Advanced Renal Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Advanced Renal Cell Carcinoma Pipeline Report

Coverage- Global
Advanced Renal Cell Carcinoma Companies- Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, Molecure S.A., Daiichi Sankyo, Janux Therapeutics, MedImmune, Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Chongqing Precision Biotech Co., Ltd, Pfizer, Exelixis, BeiGene, Xencor, and others.
Advanced Renal Cell Carcinoma Therapies- KY1044, JK08, Pembrolizumab, Savolitinib, Sunitinib, TT-10, and others.
Advanced Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Advanced Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Renal Cell Carcinoma pipeline on our website @ Advanced Renal Cell Carcinoma Emerging Drugs and Companies

Table of Content

Introduction
Executive Summary
Advanced Renal Cell Carcinoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Advanced Renal Cell Carcinoma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Belzutifan: Merck Sharp & Dohme
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
IPI-549: Infinity Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
JANX008: Janux Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Advanced Renal Cell Carcinoma Key Companies
Advanced Renal Cell Carcinoma Key Products
Advanced Renal Cell Carcinoma- Unmet Needs
Advanced Renal Cell Carcinoma- Market Drivers and Barriers
Advanced Renal Cell Carcinoma- Future Perspectives and Conclusion
Advanced Renal Cell Carcinoma Analyst Views
Advanced Renal Cell Carcinoma Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

How useful was this post?

Click on a star to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

Stay up to date
Register now to get updates on promotions and coupons

Shopping cart

×